Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.

Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism.

Combinatorial gut hormone therapy is one of the more promising strategies for identifying improved treatments for metabolic disease. Many approaches combine the established benefits of glucagon-like peptide-1 (GLP-1) agonism with one or more additional molecules with the aim of improving metabolic o...

Full description

Bibliographic Details
Main Authors: Jason A West, Anastasia Tsakmaki, Soumitra S Ghosh, David G Parkes, Rikke V Grønlund, Philip J Pedersen, David Maggs, Harith Rajagopalan, Gavin A Bewick
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0249239

Internet

https://doi.org/10.1371/journal.pone.0249239

Similar Items